Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I/II

Clearmind MedicineNasdaq: CMND

1 Drug Candidate

Clearmind Medicine is an Israeli-American biotech developing CMND-100, a proprietary oral MEAI (5-methoxy-2-aminoindane) formulation for alcohol use disorder. First patient dosed in June 2025 in their multinational Phase 1/2a trial across Yale, Johns Hopkins, and Hadassah Medical Center. Positive first cohort top-line results reported November 2025.

Drug Pipeline

1

CMND-100

Phase I/II
Alcohol Use Disorder (AUD)

Oral MEAI (5-methoxy-2-aminoindane). Phase 1/2a FDA-approved trial; first patient dosed June 2025 at Yale/Johns Hopkins. Positive Cohort 1 safety data (Nov 2025). Sites: Yale, Johns Hopkins, Hadassah.

Quick Facts

Type
Public Biotech
Ticker
Nasdaq: CMND
Lead Stage
Phase I/II
Website
Visit